Future perspectives for treating patients with geographic atrophy.

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacology

Background:

• Geographic atrophy (GA) is a severe stage of age-related macular degeneration (AMD).
• GA involves progressive atrophic lesion expansion in the retina.
• Currently, no FDA-approved treatments exist to halt GA progression.

Purpose of the Study:

• To review the progression and assessment of GA.
• To identify predictive imaging features for GA development.
• To discuss investigational complement-targeting drugs for GA.

Main Methods:

• A comprehensive literature search on geographic atrophy was performed.
• Review of studies on GA progression, assessment, and predictive imaging.
• Analysis of clinical trial data for complement-targeting drugs.

Main Results:

• GA progression correlates with declining visual function and acuity.
• Optical coherence tomography (OCT) aids in 3D atrophy assessment and early detection.
• Predictive features for GA include specific drusen, pigmentary changes, and OCT findings.
• Investigational complement inhibitors demonstrate efficacy in slowing GA progression.

Conclusions:

• Geographic atrophy leads to irreversible vision loss, highlighting a critical unmet medical need.
• Optical coherence tomography (OCT) is valuable for GA assessment and monitoring.
• Emerging complement-targeting drugs offer potential therapeutic strategies for managing GA.